Utilidad de la citología de orina para el diagnóstico del carcinoma vesical: estudio comparativo con biopsia

Castro, Manuel Alejandro; Fernández, E. Fernández; Corriente, M.C. Martín; Hernández, Sonia García; Cabrera, Hugo Álvarez-Argüelles

doi:10.1016/s0210-4806(08)73958-5

Cited by 4 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the diagnostic accuracy of voided urine cytology (VUC) is limited (3, 4). While VUC has specificities up to 98% (5), its utility as a primary detection tool is reduced because of sensitivities ranging from 40% to 76% (6). In a recent paper, we found the sensitivity of urinary cytology to be 33% (7).…”

Section: Introductionmentioning

confidence: 99%

Urinary Glycoprotein Biomarker Discovery for Bladder Cancer Detection Using LC/MS-MS and Label-Free Quantification

Yang

Feng

Shedden

et al. 2011

Clinical Cancer Research

130

118

View full text Add to dashboard Cite

Background Cancers of the urinary bladder are the fifth most commonly diagnosed malignancy in the US. Early clinical diagnosis of bladder cancer remains a major challenge and the development of non-invasive methods for detection and surveillance is desirable for both patients and health care providers. Approach In order to identify urinary proteins with potential clinical utility we enriched and profiled the glycoprotein component of urine samples using a dual-lectin affinity chromatography and LC-MS/MS platform. Results From a primary sample set obtained from 54 cancer patients and 46 controls a total of 265 distinct glycoproteins were identified with high confidence, and changes in glycoprotein abundance between groups were quantified by a label-free spectral counting method. Validation of candidate biomarker alpha-1-antitrypsin (A1AT) for disease association was performed on an independent set of 70 samples (35 cancer cases) using an ELISA. Increased levels of urinary alpha-1-antitrypsin (A1AT) glycoprotein were indicative of the presence of bladder cancer (p value < 0.0001) and augmented voided urine cytology results. A1AT detection classified bladder cancer patients with a sensitivity of 74% and specificity of 80%. Summary The described strategy can enable higher resolution profiling of the proteome in biological fluids by reducing complexity. Application of glycoprotein enrichment provided novel candidates for further investigation as biomarkers for the non-invasive detection of bladder cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Urinary Glycoprotein Biomarker Discovery for Bladder Cancer Detection Using LC/MS-MS and Label-Free Quantification

Yang

Feng

Shedden

et al. 2011

Clinical Cancer Research

130

118

View full text Add to dashboard Cite

show abstract

Citodiagnóstico urinario: aspectos de interés para el citotécnico

Girón

Alonso

2012

Revista Española de Patología

View full text Add to dashboard Cite

Diagnostic Value of a Urine-Based Tumor Marker for Screening Lower Urinary Tract in Low-Risk Patients with Asymptomatic Microscopic Hematuria

Sağnak

Ersoy²,

Gucuk³

et al. 2011

Urol Int

View full text Add to dashboard Cite

Background: To evaluate the use of NMP22 BladderChek® (NMP22BC) as an initial test in comparison to voided urine cytology for screening subjects with asymptomatic microscopic hematuria (AMH); those who are <40 years of age and have a low risk for bladder cancer based on a non-smoking history, and by discussing the guidelines on this subject. Methods: From October 2005 to September 2007, 164 patients (56 male, 108 female) were evaluated. Patients with risk factors according to AUA Best Practice Policy Recommendations on AMH were strictly excluded from the study. For upper urinary tract imaging, ultrasonography (USG) was performed and prior to the cystoscopic procedure freshly voided urine was sampled for urine cytology and NMP22BC assay in all patients. Biopsy was performed if suspicious lesions were seen or positive cytology was obtained. Results: The mean age was 30.8 years. As some benign urological pathologies were detected in 21 patients by USG, NMP22BC was positive in 26 patients where the cytology was confirmed as atypia in 5. Two TaG1 tumors were detected cystoscopically in a 39-year-old man and a 33-year-old woman where the NMP22BC test was positive and the cytology was negative in both patients. NMP22BC tests sensitivity, PPV and NPV values were detected to be higher compared to cytology and the likelihood ratio was 6.75. Conclusion: We recommend in evaluation of low-risk patients with AMH that, as an initial test, two non-invasive and cost-effective methods be chosen: an upper tract imaging by USG as recommended by guidelines, followed by an NMP22BC test for lower tract investigation instead of urine cytology.

show abstract

Utilidad de la citología de orina para el diagnóstico del carcinoma vesical: estudio comparativo con biopsia

Cited by 4 publications

References 16 publications

Urinary Glycoprotein Biomarker Discovery for Bladder Cancer Detection Using LC/MS-MS and Label-Free Quantification

Urinary Glycoprotein Biomarker Discovery for Bladder Cancer Detection Using LC/MS-MS and Label-Free Quantification

Citodiagnóstico urinario: aspectos de interés para el citotécnico

Diagnostic Value of a Urine-Based Tumor Marker for Screening Lower Urinary Tract in Low-Risk Patients with Asymptomatic Microscopic Hematuria

Contact Info

Product

Resources

About